Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Puma Biotechnology cash
Cash and short-term investments held at the end of each period.
Puma Biotechnology's cash was $86.80M at Jun 30, 2026. For fiscal 2025 it was $91.63M, up 5.5% from the year before. Over ten years it grew -8.2% a year on average. The highest annual figure on record is $229.40M in fiscal 2016.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.63M | +5.5% |
| FY2024 | Dec 31, 2024 | $86.84M | +77.5% |
| FY2023 | Dec 31, 2023 | $48.92M | +5.1% |
| FY2022 | Dec 31, 2022 | $46.55M | -33.4% |
| FY2021 | Dec 31, 2021 | $69.85M | -12.5% |
| FY2020 | Dec 31, 2020 | $79.81M | -28.5% |
| FY2019 | Dec 31, 2019 | $111.64M | -32.5% |
| FY2018 | Dec 31, 2018 | $165.42M | +102.5% |
| FY2017 | Dec 31, 2017 | $81.70M | -64.4% |
| FY2016 | Dec 31, 2016 | $229.40M | +6.3% |
| FY2015 | Dec 31, 2015 | $215.89M | +52.8% |
| FY2014 | Dec 31, 2014 | $141.33M | +68.4% |
| FY2013 | Dec 31, 2013 | $83.95M | -38.9% |
| FY2012 | Dec 31, 2012 | $137.41M | +157.4% |
| FY2011 | Dec 31, 2011 | $53.38M | – |
| FY2010 | Dec 31, 2010 | $0 | -100.0% |
| FY2009 | Dec 31, 2009 | $2.41K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $86.80M | -2.2% |
| Q1 FY2026 | Mar 31, 2026 | $91.66M | +11.6% |
| Q4 FY2025 | Dec 31, 2025 | $91.63M | +5.5% |
| Q3 FY2025 | Sep 30, 2025 | $88.43M | -1.6% |
| Q2 FY2025 | Jun 30, 2025 | $88.74M | -0.1% |
| Q1 FY2025 | Mar 31, 2025 | $82.12M | +2.9% |
| Q4 FY2024 | Dec 31, 2024 | $86.84M | +77.5% |
| Q3 FY2024 | Sep 30, 2024 | $89.91M | +86.3% |
| Q2 FY2024 | Jun 30, 2024 | $88.79M | +86.3% |
| Q1 FY2024 | Mar 31, 2024 | $79.82M | +69.6% |
| Q4 FY2023 | Dec 31, 2023 | $48.92M | +5.1% |
| Q3 FY2023 | Sep 30, 2023 | $48.27M | +4.6% |
| Q2 FY2023 | Jun 30, 2023 | $47.65M | +3.8% |
| Q1 FY2023 | Mar 31, 2023 | $47.07M | +2.6% |
| Q4 FY2022 | Dec 31, 2022 | $46.55M | -33.4% |
| Q3 FY2022 | Sep 30, 2022 | $46.14M | -33.9% |
| Q2 FY2022 | Jun 30, 2022 | $45.92M | -57.9% |
| Q1 FY2022 | Mar 31, 2022 | $45.86M | -57.9% |
| Q4 FY2021 | Dec 31, 2021 | $69.85M | -12.5% |
| Q3 FY2021 | Sep 30, 2021 | $69.84M | -35.9% |
| Q2 FY2021 | Jun 30, 2021 | $108.98M | +1.6% |
| Q1 FY2021 | Mar 31, 2021 | $109.05M | +8.4% |
| Q4 FY2020 | Dec 31, 2020 | $79.81M | -28.5% |
| Q3 FY2020 | Sep 30, 2020 | $109.02M | -1.3% |
| Q2 FY2020 | Jun 30, 2020 | $107.27M | -8.8% |
| Q1 FY2020 | Mar 31, 2020 | $100.56M | -33.1% |
| Q4 FY2019 | Dec 31, 2019 | $111.64M | -32.5% |
| Q3 FY2019 | Sep 30, 2019 | $110.44M | -13.7% |
| Q2 FY2019 | Jun 30, 2019 | $117.67M | -12.5% |
| Q1 FY2019 | Mar 31, 2019 | $150.40M | +91.5% |
| Q4 FY2018 | Dec 31, 2018 | $165.42M | +102.5% |
| Q3 FY2018 | Sep 30, 2018 | $127.95M | +20.4% |
| Q2 FY2018 | Jun 30, 2018 | $134.51M | -11.3% |
| Q1 FY2018 | Mar 31, 2018 | $78.55M | -59.5% |
| Q4 FY2017 | Dec 31, 2017 | $81.70M | -64.4% |
| Q3 FY2017 | Sep 30, 2017 | $106.30M | -2.4% |
| Q2 FY2017 | Jun 30, 2017 | $151.60M | – |
| Q1 FY2017 | Mar 31, 2017 | $194.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $229.40M | – |
| Q3 FY2016 | Sep 30, 2016 | $108.93M | – |
See a number that looks wrong?